Many individuals who have successfully lost weight using GLP-1 agonist drugs, such as Ozempic and Wegovy, are finding it difficult to discontinue their use. According to a report by the BBC, this dependency is largely due to a resurgence of hunger that leads to weight regain, suggesting that long-term use of these medications may be necessary for many patients.
Tanya Hall, a Wegovy user who has lost approximately 38 kg (about 83 pounds), expressed her struggles with the medication. “For the first 38 years of my life, I was overweight — now I’m six stone lighter,” she stated. Hall mentioned feeling a sense of addiction to the drug, as it allows her to maintain control over her weight.
Research indicates that patients who stop using GLP-1 medications often regain a significant portion of their lost weight. A study by Novo Nordisk, the manufacturer of Ozempic, found that individuals typically regain two-thirds of the weight they lost once they discontinue the medication. Physician Hussain Al-Zubaidi noted that he has observed patients regaining between 60% to 80% of their lost weight.
The implications of these findings have led some high-profile users, such as Oprah Winfrey, to consider long-term use of these medications. Winfrey shared her thoughts with People Magazine, stating, “It’s going to be a lifetime thing. I’ve proven to myself I need it.” She compared her need for GLP-1 medications to her reliance on high blood pressure medication, underscoring the chronic nature of obesity for many individuals.
Despite the challenges, experts suggest that there is hope for those who wish to stop using these drugs. Al-Zubaidi recommends that patients develop an “exit strategy” that includes adopting healthier lifestyle changes while still on the medications. These changes can help sustain weight loss after discontinuation.
Ellen Ogley is a case in point. She lost 48.5 pounds while using Eli Lilly’s GLP-1 drug, Mounjaro. During her treatment, Ogley focused on healthier eating habits and regular exercise. She has successfully maintained her weight loss even after stopping the medication. “I want people to know that life after Mounjaro can be sustainable as well,” she remarked.
The situation highlights a broader conversation about the long-term management of obesity and the role of medications in this process. As more individuals turn to GLP-1 drugs for weight loss, understanding the need for ongoing lifestyle changes becomes increasingly vital. The experiences of users like Hall and Ogley demonstrate both the challenges and possibilities in navigating life with or without these medications.
